Rep. Park Hee-seung, Democratic Party of Korea [Photo=Park Hee-seung's office]
Rep. Park Hee-seung of the Democratic Party of Korea, a member of the National Assembly's Health and Welfare Committee, stated that the global pharmaceutical and biotechnology industries are at a significant turning point driven by artificial intelligence (AI). He explained that AI is enhancing research and development (R&D) efficiency throughout the entire drug development process and is leading to structural changes in the industry.
In a written address at the 16th Global Healthcare Forum held on May 14 at the Korea Press Center in Jung-gu, Seoul, hosted by Aju Economy, Park said, "Technological advancements are a key driver facilitating licensing out and mergers and acquisitions (M&A) with global big pharma companies."
He emphasized that the K-bio industry must move beyond mere technology validation to establish a comprehensive value chain that attracts capital and enables global expansion. "To secure competitiveness in the rapidly changing global market, strategic policy support and close collaboration among industry, academia, and research institutions are more crucial than ever," he added.
As a member of the Health and Welfare Committee, Park pledged to listen to voices from the field, stating, "I will work to create effective policy foundations that allow companies to shorten drug development timelines based on AI technology and successfully enter the global market."
He concluded, "I hope today's event serves as an opportunity to seek concrete strategies to enhance the global competitiveness of the K-pharmaceutical and bio industries and for the public and private sectors to pool their wisdom."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.